Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study

Kuroda, Naoto; Yamashita, M; Kakehi, Yoshiyuki; Hes, Ondřej; Michal, Michal; Lee, Gang-Hong

doi:10.1007/s00795-010-0496-1

Cited by 28 publications

(23 citation statements)

References 18 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28][29][30][31] Gains of chromosome 3, in particular, have been among the more consistent findings. Although gains of chromosomes 7 and/or 17 in some tumors have been reported, gains of chromosomes 1, 2, 3, 6, 7, 16, and Y were also frequently observed.…”

Section: Proposed New Epithelial Neoplasms Tubulocystic Renal Cell Camentioning

confidence: 72%

“…21,29,32,33 However, although the mechanism is not clear, VHL transcripts are underexpressed, and SNParray and microarray comparative genomic hybridization analyses have confirmed such findings in 2 different series. 21,29,32,33 However, although the mechanism is not clear, VHL transcripts are underexpressed, and SNParray and microarray comparative genomic hybridization analyses have confirmed such findings in 2 different series.…”

Section: Proposed New Epithelial Neoplasms Tubulocystic Renal Cell Camentioning

confidence: 99%

“…20,21,24,[27][28][29] However, a specific IHC profile is not required to make this diagnosis. ACD-RCCs stain diffusely positive for AMACR and negative or, at the most, only very focally positive for CK7.…”

Section: Proposed New Epithelial Neoplasms Tubulocystic Renal Cell Camentioning

confidence: 99%

See 2 more Smart Citations

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

Srigley¹,

Delahunt²,

Eble³

et al. 2013

American Journal of Surgical Pathology

Self Cite

946

727

View full text Add to dashboard Cite

The classification working group of the International Society of Urological Pathology consensus conference on renal neoplasia was in charge of making recommendations regarding additions and changes to the current World Health Organization Classification of Renal Tumors (2004). Members of the group performed an exhaustive literature review, assessed the results of the preconference survey and participated in the consensus conference discussion and polling activities. On the basis of the above inputs, there was consensus that 5 entities should be recognized as new distinct epithelial tumors within the classification system: tubulocystic renal cell carcinoma (RCC), acquired cystic disease-associated RCC, clear cell (tubulo) papillary RCC, the MiT family translocation RCCs (in particular t(6;11) RCC), and hereditary leiomyomatosis RCC syndrome-associated RCC. In addition, there are 3 rare carcinomas that were considered as emerging or provisional new entities: thyroid-like follicular RCC; succinate dehydrogenase B deficiency-associated RCC; and ALK translocation RCC. Further reports of these entities are required to better understand the nature and behavior of these highly unusual tumors. There were a number of new concepts and suggested modifications to the existing World Health Organization 2004 categories. Within the clear cell RCC group, it was agreed upon that multicystic clear cell RCC is best considered as a neoplasm of low malignant potential. There was agreement that subtyping of papillary RCC is of value and that the oncocytic variant of papillary RCC should not be considered as a distinct entity. The hybrid oncocytic chromophobe tumor, which is an indolent tumor that occurs in 3 settings, namely Birt-Hogg-Dubé Syndrome, renal oncocytosis, and as a sporadic neoplasm, was placed, for the time being, within the chromophobe RCC category. Recent advances related to collecting duct carcinoma, renal medullary carcinoma, and mucinous spindle cell and tubular RCC were elucidated. Outside of the epithelial category, advances in our understanding of angiomyolipoma, including the epithelioid and epithelial cystic variants, were considered. In addition, the apparent relationship between cystic nephroma and mixed epithelial and stromal tumor was discussed, with the consensus that these tumors form a spectrum of neoplasia. Finally, it was thought that the synovial sarcoma should be removed from the mixed epithelial and mesenchymal category and placed within the sarcoma group. The new classification is to be referred to as the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia.

show abstract

Section: Proposed New Epithelial Neoplasms Tubulocystic Renal Cell Camentioning

confidence: 72%

Section: Proposed New Epithelial Neoplasms Tubulocystic Renal Cell Camentioning

confidence: 99%

See 1 more Smart Citation

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

Srigley¹,

Delahunt²,

Eble³

et al. 2013

American Journal of Surgical Pathology

Self Cite

946

727

View full text Add to dashboard Cite

show abstract

“…The molecular basis for ACD-associated RCC is not fully understood, however, these tumors often show variable chromosomal gains, including chromosomes 7 and 17 (which are more classically associated with PRCC). [56][57][58] Indeed, ACD-associated RCC can show overlapping morphologic and immunophenotypic features with PRCC, and although these tumors frequently express AMACR and CD10, ACD-associated RCC is usually negative for CK7 expression. [56][57][58] In general, ACD-associated RCC is an indolent tumor; however, a subset of patients with ACD-associated RCC may develop metastatic disease.…”

Section: Rcc With Papillary Architecturementioning

confidence: 99%

“…[56][57][58] Indeed, ACD-associated RCC can show overlapping morphologic and immunophenotypic features with PRCC, and although these tumors frequently express AMACR and CD10, ACD-associated RCC is usually negative for CK7 expression. [56][57][58] In general, ACD-associated RCC is an indolent tumor; however, a subset of patients with ACD-associated RCC may develop metastatic disease. 15 Collecting duct carcinoma is an uncommon RCC subtype that arises from the distal collecting system of the kidney and has an aggressive clinical course.…”

Section: Rcc With Papillary Architecturementioning

confidence: 99%

Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification

Udager

Mehra²

2016

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Molecular and morphologic interrogation has driven a much-needed reexamination of renal cell carcinoma (RCC). Indeed, the recently released 2016 World Health Organization classification now recognizes 12 distinct RCC subtypes, as well as several other emerging/provisional RCC entities. From a clinical perspective, accurate RCC classification may have important implications for patients and their families, including prognostic risk stratification, targeted therapeutics selection, and identification for genetic testing. In this review, we provide a conceptual framework for approaching RCC diagnosis and classification by categorizing RCCs as tumors with clear cytoplasm, papillary architecture, and eosinophilic (oncocytic) cytoplasm. The currently recognized 2016 World Health Organization classification for RCC subtypes is briefly discussed, including new diagnostic entities (clear cell papillary RCC, hereditary leiomyomatosis and RCCassociated RCC, succinate dehydrogenase-deficient RCC, tubulocystic RCC, and acquired cystic disease-associated RCC) and areas of evolving RCC classification, such as transcription elongation factor B subunit 1 (TCEB1)-mutated RCC/RCC with angioleiomyoma-like stroma/ RCC with leiomyomatous stroma, RCC associated with anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangement, thyroidlike follicular RCC, and RCC in neuroblastoma survivors. For each RCC subtype, relevant clinical, molecular, gross, and microscopic findings are reviewed, and ancillary studies helpful for its differential diagnosis are presented, providing a practical approach to modern RCC classification.

show abstract

New entities, new technologies, new findings: A review of the cytologic features of recently established subtypes of renal cell carcinoma

Robila

Kraft

Smith

2019

Cancer Cytopathology

View full text Add to dashboard Cite

Several new renal tumor types with distinctive pathologic, epidemiologic, and genetic signatures have recently been adopted in the fourth edition of the World Health Organization classification. In succeeding years, the cytologic features of most of these new types have been described, adding to the trend of increasing diagnostic accuracy for most common renal cell carcinoma subtypes and the important diagnostic role of cytologic sampling in the management and personalization of therapy. The current article reviews the cytologic findings from these recently established renal cell carcinoma subtypes. Emphasis is placed on cytologic diagnostic clues, confirmatory ancillary testing, salient differential diagnoses, and challenges that can be encountered in an attempt to render accurate interpretations in small samples.

show abstract

Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study

Cited by 28 publications

References 18 publications

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification

New entities, new technologies, new findings: A review of the cytologic features of recently established subtypes of renal cell carcinoma

Contact Info

Product

Resources

About